Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, our results demonstrate novel evidence that the paracrine NGF/TrkA axis favors EMT and confers EGFR-targeted therapeutic resistance in HNSCC.
|
31838083 |
2020 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Targeting EGFR in combination with conventional chemotherapy might be a promising strategy for the treatment of HNSCC through elimination of cancer stem cells.
|
31823521 |
2020 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN.
|
31676542 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, we show that EGFR blockade inhibits <i>EREG</i> expression, and that <i>EREG</i> knock-down decreases basal cell clonogenic survival, suggesting that <i>EREG</i> expression could be a predictive functional marker of sensitivity to EGFR blockade in basal-like HNSCC.
|
31181806 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The most common abnormalities downstream from EGFR in HNSCC are in the PI3K pathway, activated via loss of expression of the regulator PTEN, or via PI3K mutation.
|
30926065 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells.
|
31462653 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cetuximab is a chimeric monoclonal antibody against epidermal growth factor receptor (EGFR) and it is approved for treatment of human colorectal cancer and squamous cell carcinoma of head and neck.
|
31112673 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mechanism of action of Cetuximab could be immune-mediated rather than EGFR inhibition and EGFR may not necessarily be a therapeutic target in SCCHN.
|
30701564 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mechanistically, high levels of Arf1 activity are maintained by binding to phosphorylated EGFR which is localized on HNSCC cell plasma membrane.
|
30777099 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics.
|
30858165 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression.
|
31827134 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA LINC00052 regulates miR-608/EGFR axis to promote progression of head and neck squamous cell carcinoma.
|
31639333 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, the present data suggest that cetuximab treatment in combination with ALT-803 in patients with EGFR-positive SCCHN may result in significant NK cell activation and have important anti-tumor activity.
|
31338557 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using metabolic imaging, we were able to identify hyperpolarized <sup>13</sup>C-pyruvate as a potential marker for response and resistance to the EGFR inhibitor in HNSCC.
|
31831557 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using a novel cohort of patients with head and neck squamous cell carcinoma (HNSCC), we investigated mechanisms of immune escape from epidermal growth factor receptor-specific monoclonal antibody (mAb) therapy.
|
30828910 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Similarly, EGFR was analyzed in HNSCCs (N = 21).
|
31345374 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuximab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC).
|
31554698 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
|
31299389 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) overexpression is common in head and neck squamous cell carcinoma.
|
30700700 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck.
|
31561451 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Trials on assessing the benefits of EGFR inhibitors in head and neck squamous cell carcinoma (HNSCC) patients have gradually been published.
|
31239839 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
We systematically searched literature for randomized controlled trials comparing chemotherapy or radiotherapy with versus without EGFR inhibitors in locoregionally advanced, recurrent, or metastatic HNSCCs.
|
30819445 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cetuximab, an EGFR-blocking antibody, is currently approved for treatment of metastatic head and neck squamous cell carcinoma (HNSCC), but its response rate is limited.
|
31578313 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
We therefore sought to identify cellular mechanisms that cause resistance to EGFR inhibition and radiotherapy in HNSCC.
|
31387891 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we identified two enhancers (CE1 and CE2) present within the first intron of the <i>EGFR</i> gene in models of glioblastoma (GBM) and head and neck squamous cell carcinoma (HNSCC).
|
31444232 |
2019 |